Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

A fast-rising form of breast cancer that's harder to detect on mammograms now makes up more than one in ten cases in the United States, according to a new report from the American Cancer Society (ACS) ...

Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).

The Breast International Group (BIG) 1-98 study evaluated adjuvant endocrine therapy in postmenopausal women who had hormone receptor-positive early-stage breast cancer. The study participants were ...

The SNMMI Mars Shot Research Fund is pleased to announce that Randy Yeh, MD, a radiologist and nuclear medicine physician at Mount Sinai Health System, associate professor of radiology, and chief of ...